Specialty Pharmacy Research & Clinical Data
Clinical evidence · FDA data · Real-world outcomes · Industry statistics
About This Resource
BiologicHealthPlus compiles authoritative clinical research, FDA prescribing data, and real-world evidence to help patients, caregivers, and healthcare providers make informed decisions about biologic therapy. All data is sourced from peer-reviewed literature, FDA databases, and leading medical organizations.
Key Clinical Statistics
~50M
Americans affected by autoimmune disease
Source: AARDA
$84K+
Annual Humira list price before biosimilars
Source: WAC data
8+
FDA-approved Humira biosimilars (2026)
Source: FDA
55%
Of total US drug spend on specialty drugs
Source: IQVIA 2025
~90%
PASI 90 response — IL-23 inhibitors (psoriasis)
Source: Clinical trials
~30%
Initial PA denial rate for biologics
Source: AMA survey
Biologic Efficacy by Drug Class
| Drug Class | Examples | Key Indication | Typical Efficacy | Key Evidence |
|---|---|---|---|---|
| IL-23 Inhibitors | Skyrizi, Tremfya | Plaque Psoriasis | ~90% PASI 90 | ULTIMMA, VOYAGE trials |
| IL-17 Inhibitors | Cosentyx, Bimzelx | Psoriasis / AS | ~77–91% PASI 90 | FIXTURE, BE VIVID trials |
| TNF-α Inhibitors | Humira, Enbrel | RA / IBD / Psoriasis | ACR20 ~60–70% | 25+ years real-world data |
| JAK Inhibitors | Rinvoq, Xeljanz | RA / UC / Psoriasis | ACR20 ~65–75% | SELECT, ORAL Strategy trials |
| Anti-integrin | Entyvio | IBD (UC / Crohn's) | ~50% clinical remission | GEMINI trials |
| IL-4/13 Inhibitors | Dupixent | Atopic Dermatitis | ~75% IGA 0-1 | SOLO, CHRONOS trials |
| IL-6 Inhibitors | Actemra, Kevzara | Rheumatoid Arthritis | ACR20 ~65–70% | MONARCH, SARIL-RA trials |
| TYK2 Inhibitors | Sotyktu | Plaque Psoriasis | ~58% PASI 90 | POETYK PSO trials |
Biosimilar Market Data
| Reference Biologic | FDA-Approved Biosimilars | Launch Year | Price Impact |
|---|---|---|---|
| Humira (adalimumab) | 8+ biosimilars | 2023 | ~85% WAC reduction (some) |
| Remicade (infliximab) | 5+ biosimilars | 2016–2019 | ~30–40% reduction |
| Stelara (ustekinumab) | 2+ biosimilars | 2023–2024 | Pricing evolving |
| Enbrel (etanercept) | 0 (US market) | N/A (patent protected) | No current competition |
Authoritative Research Sources
🏛️ FDA Biosimilar Program
Official FDA guidance on biosimilar approvals, interchangeability, and labeling
🔬 NIH/PubMed Research
Peer-reviewed literature on biologic mechanisms, efficacy, and safety
🏥 ACR Clinical Guidelines
American College of Rheumatology treatment guidelines for RA, AS, PsA
🫁 AGA IBD Guidelines
American Gastroenterological Association biologic therapy guidelines for IBD
🩹 AAD Psoriasis Guidelines
American Academy of Dermatology biologic treatment guidelines for psoriasis
💰 KFF Drug Pricing Research
Kaiser Family Foundation analysis of specialty drug pricing and access
🏛️ CMS/Medicare Drug Data
CMS specialty drug coverage, Medicare Part D data, and Inflation Reduction Act
🌍 WHO Biosimilar Guidelines
World Health Organization guidelines on biosimilar evaluation and approval
📬 Submit Research or Request Data
Healthcare researchers, journalists, and academic institutions may contact BiologicHealthPlus for specialty pharmacy data, expert commentary, or research collaboration.
Contact Research Team →